Spirulina and hereditary angioedema: bradykinin mechanism, C1-INH deficiency, and safety assessment

HAE mechanism: bradykinin, not histamine

C1-esterase inhibitor (C1-INH) deficiency: HAE types I and II involve deficient or dysfunctional C1-INH (SERPING1 gene). C1-INH normally inhibits activated factor XII (Hageman factor) and plasma kallikrein. Without adequate C1-INH, factor XIIa cleaves prekallikrein to kallikrein; kallikrein cleaves high-molecular-weight kininogen (HMWK) to release bradykinin. Excess bradykinin activates bradykinin B2 receptors on vascular endothelium, causing massive local plasma extravasation — the angioedema attack.
HAE with normal C1-INH (type III/oestrogen-dependent): Involves FXII mutations or other genetic causes of excess kallikrein activity. Oestrogen upregulates FXII gene expression — explaining why this type worsens dramatically with the oral contraceptive pill, HRT, and pregnancy. Spirulina has no oestrogenic activity and does not upregulate FXII.
Why histamine mechanisms are irrelevant: Spirulina’s GLA pathway effects on 5-LOX and leukotriene production, its potential histamine content in degraded products, and its mast cell interactions all operate on the histamine/leukotriene arm of acute inflammation — a completely separate pathway from bradykinin-mediated angioedema.

Oxidative stress and factor XII activation: Factor XII can be activated by negatively charged surfaces and by oxidative stress. Phycocyanobilin’s NOX2 inhibition reduces endothelial oxidative stress, which is directionally anti-activating for FXII. This is a speculative protective effect, not a clinical claim.
No documented HAE triggers from spirulina: There are no case reports or clinical evidence of spirulina triggering HAE attacks. The known triggers are oestrogen, ACE inhibitors, physical stress, emotional stress, minor trauma, and infections — none of which are mechanistically provided by spirulina.
Initial caution: As with any new food supplement in a condition characterised by unpredictable attacks, start at a low dose (1–2 g/day) and monitor for any attack increase over 4–6 weeks. If attack frequency increases: stop and report to the HAE specialist clinic. This is precautionary, not based on a specific mechanistic concern.

C1-INH concentrate replaces the deficient protein for acute attack treatment. Administered IV; no oral pharmacokinetic interaction with spirulina. No documented interaction.

Icatibant blocks the bradykinin B2 receptor for acute attack treatment. No CYP pharmacokinetic interaction with spirulina. No documented interaction.

Lanadelumab is a monoclonal antibody prophylaxis (subcutaneous, every 2–4 weeks). Not metabolised by CYP enzymes. No pharmacokinetic interaction with spirulina. Lanadelumab reduces immunological surveillance less than immunosuppressants — NK stimulation concern from spirulina is low in this context.

Tranexamic acid inhibits fibrinolysis. Spirulina’s mild antiplatelet activity may mildly counteract tranexamic acid’s haemostatic effects, but at standard 3–5 g/day doses this is not expected to be clinically significant. Inform HAE specialist if on tranexamic acid prophylaxis.

ACE inhibitors (lisinopril, ramipril, enalapril) block bradykinin degradation and are absolutely contraindicated in HAE (they trigger attacks). Spirulina has no ACE inhibitory activity documented in clinical settings and is not expected to interact with this mechanism.

HAE on lanadelumab or C1-INH prophylaxis: 3–5 g/day is appropriate; no interaction with these agents; discuss with HAE clinic as routine supplement disclosure
HAE type III (oestrogen-sensitive): spirulina has no oestrogenic activity — this is a key safety point; confirm with your endocrinologist or HAE specialist that the supplement has no hormonal components
Start at 1–2 g/day with monitoring for attack frequency over the first 4–6 weeks; increase if no change in attack pattern
Not a first-line supplement in uncontrolled or severe HAE until attacks are well-managed with medical prophylaxis